Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

French minister gags on EMA contraceptives pill verdict

This article was originally published in Scrip

Executive Summary

The European Medicines Agency said there is no need to change the safety profile of combined oral contraceptives in an update responding to media reports on the risks of venous thromboembolism. However, the French health minister has called for third and fourth generation contraceptive pills to be used if earlier (and cheaper) contraceptives are inappropriate.

You may also be interested in...



German HTA Queries Polivy Benefits Amid Lack Of Evidence

Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.

Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy

In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.

New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies

New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC020030

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel